W. R. Grace expands CDMO fine-chemical capacity in South Haven, MI
- Grace completed a 21-month expansion at its South Haven, MI CDM facility and held a ribbon cutting with executives, community leaders and 200+ employees.
- The expansion increases capacity by 25% and adds a 4,000-gallon HASTELLOY® centrifuge plus three 4,000-gallon multi-use chemical reactors.
- The site produces APIs, regulatory starting materials (RSMs) and drug intermediates at kilo-to-ton scale in compliance with FDA cGMP.
- South Haven integrates with Grace’s Tyrone, PA facility to provide flexible U.S.-based supply for pharmaceutical and nutraceutical customers.
Project completion
Grace opened its expanded fine chemical contract development and manufacturing (CDM) facility in South Haven, MI after a 21-month project and marked the milestone with a ribbon cutting attended by company executives, local leaders and more than 200 employees.
Capacity and equipment
The expansion adds 25% more capacity and new large-scale equipment including a 4,000-gallon HASTELLOY® centrifuge and three 4,000-gallon multi-use chemical reactors to support increased Active Pharmaceutical Ingredient (API) demand.
Capabilities and market focus
The South Haven site serves the pharmaceutical market—producing APIs, regulatory starting materials (RSMs) and drug intermediates—covering quantities from kilos to tons and supporting stages from research and development to clinical trials, scale-up and commercial production.
Compliance and supply-chain integration
The facility operates in compliance with FDA current Good Manufacturing Practice (cGMP) regulations and integrates with Grace’s Tyrone, PA site to offer customers flexibility within a U.S.-based supply chain.
Source: Grace
